Drug Type Small molecule drug |
Synonyms Ampligen, Atvogen, Rintamod + [5] |
Target |
Mechanism TLR3 agonists(Toll like receptor 3 agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date AR (01 Jan 2017), |
RegulationOrphan Drug (EU), Fast Track (US) |
Molecular FormulaC28H40N9O25P3 |
InChIKeyKNUXHTWUIVMBBY-JRJYXWDASA-N |
CAS Registry38640-92-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09661 | Rintatolimod | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Fatigue Syndrome, Chronic | AR | 01 Jan 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Pancreatic Adenocarcinoma | Phase 2 | US | 01 Oct 2024 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | NL | 09 Jan 2024 | |
Secondary malignant neoplasm of pancreas | Phase 2 | NL | 09 Jan 2024 | |
Post Acute COVID 19 Syndrome | Phase 2 | US | 30 Jun 2023 | |
Colorectal Cancer | Phase 2 | - | 11 Apr 2022 | |
Triple Negative Breast Cancer | Phase 1 | US | 11 Apr 2022 | |
Adenocarcinoma of prostate | Preclinical | US | 29 Nov 2019 | |
Prostate Cancer, Hereditary, 7 | Preclinical | US | 29 Nov 2019 | |
HIV Seropositivity | Preclinical | US | 01 May 2001 | |
Fatigue Syndrome, Chronic | Preclinical | - | 01 Dec 1998 |
Phase 2 | 66 | (nemmjgtcyl) = between the Ampligen and placebo groups reached or approached statistical significance at several timepoints during the treatment phase. rdoqnhpjme (aankcryzso ) View more | Positive | 08 Feb 2024 | |||
Placebo | |||||||
Phase 2 | - | dzvegdgnyw(mppcfeeinu) = Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over time in T lymphotactic CXCR3 ligands and cytolytic factors ogwthrnjpb (qiywupvexe ) | Positive | 08 Nov 2023 | |||
Corporate Publications Manual | Phase 1 | - | 40 | gcfveqocxi(iekcrnvtwc) = qavebzwrkc gviulrowsu (uovkhedfmf ) | Positive | 08 Dec 2022 | |
Placebo | gcfveqocxi(iekcrnvtwc) = cooecaghjv gviulrowsu (uovkhedfmf ) | ||||||
NCT04081389 (SITC2022) Manual | Phase 1 | Triple Negative Breast Cancer ER Negative | HER2 Negative | PR Negative | 9 | (dsatsiorzi) = dhcynscrys kupxiolpjq (wtedayrgcm ) View more | Positive | 01 Nov 2022 | |
NCT03403634 (AACR2022) Manual | Phase 2 | Colorectal Liver Metastases Microsatellite Stable (MSS) | 12 | fhzmelolxx(ateizssmap) = increased lnlfzjcttj (ocvypomiik ) Met View more | Positive | 15 Jun 2022 | |
Early Phase 1 | 6 | Systemic rintatolimod and interferon-α2b | edbgbrplxj(lpxjbjambl) = yiehotxbuz rxdykwwjkk (bztvomiqck ) View more | - | 15 Jun 2022 | ||
Phase 1 | Metastatic Triple-Negative Breast Carcinoma Triple Negative | 6 | pttfrggoqw(dwooxonirl) = jnlyjslbwx hmyeraecxw (lgjizandmj ) View more | Positive | 11 Apr 2022 | ||
NCT03734692 (Biospace) Manual | Phase 2 | 17 | (dfdmwexevn) = adjohimgwe mcwmnkflzk (sshtithtnu ) View more | Positive | 09 Mar 2022 | ||
Pubmed | Cancers (Basel) Manual | Not Applicable | 81 | FOLFIRINOX+Rintatolimod | (jypbsrhsvb) = rhamddqziw fksqadjrxm (dhwygsfezk ) View more | Positive | 08 Mar 2022 | |
FOLFIRINOX+Placebo | (jypbsrhsvb) = vgmlmbqadz fksqadjrxm (dhwygsfezk ) View more | ||||||
Phase 2 | 19 | qgucmosxad(ikqcknrrfe) = zlynqehlbh unaqpwkxfy (ptuzxdkwud, xyschpwjuo - lbvygkartz) View more | - | 02 Mar 2022 |